Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, antibody based therapy, e.g. lapatinib, bevacizumab, erlotinib, imatinib, that are sometimes offered on a compassionate-use basis to NF2 patients)
